TABLE 3.
Baseline general characteristics of the study participants according to the assigned treatment1
| General characteristics | HF (n = 30) | IF (n = 30) | LF (n = 30) | P |
| Sex (M/F), n | 12/18 | 11/19 | 14/16 | 0.725 |
| Age, y (range) | 70.00 ± 0.882 (65–85) | 68.67 ± 0.67 (61–77) | 69.97 ± 0.77 (62–79) | 0.391 |
| BMI range, kg/m2 | 19–30 | 21–30 | 20–30 | |
| Hypertension, n (%) | 16 (53) | 19 (63) | 15 (50) | 0.557 |
| Treated | 12 (75) | 13 (68) | 11 (73) | 0.870 |
| Pharmacologic treatments | ||||
| ACE-Is | 7 (58) | 8 (62) | 6 (54) | 0.830 |
| ARBs | 2 (17) | 0 (0) | 2 (18) | 0.351 |
| CCBs | 5 (42) | 6 (46) | 4 (36) | 0.787 |
| Diuretics | 3 (25) | 4 (31) | 3 (27) | 0.894 |
| Diabetes, n (%) | 5 (16) | 5 (16) | 7 (23) | 0.748 |
| Oral agents | 4 (80) | 4 (80) | 6 (86) | 0.713 |
| Insulin | None | None | None | |
| Hypercholesterolemia, n (%) | 3 (10) | 7 (23) | 6 (20) | 0.372 |
| Former smoker, n (%) | 4 (13) | 3 (10) | 6 (20) | 0.533 |
1
ANOVA was used for continuous variables; chi-square test was used for categorical variables. ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker; CCB, calcium channel blocker; HF, high flavanol intake; IF, intermediate flavanol intake; LF, low flavanol intake.
2
Mean ± SE (all such values).